Cholesterol Lowering Effect of Simvastatin in Patients with Normal and Impaired Renal Function

  • G. Wambach
  • R. Jacob
  • E. Danull
  • H. Eckardt
Conference paper
Part of the Recent Developments in Lipid and Lipoprotein Research book series (LIPID)


The cholesterol lowering effect of simvastatin was studied in hyperlipidaemic patients with normal and impaired renal function. 10 patients (group A, 4 male/6 female, aged 57 ± 8 years, serum creatinine 0.95 ± 0.10 mg/dl) and 10 patients with chronic interstitial nephritis (group B, 4 male, 6 female, aged 64 ± 6 years, serum creatinine 2.13 ± 0.65 mg/dl) were treated with simvastatin for a period of 12 weeks after a placebo period of 4 weeks. Total cholesterol was reduced from 308 ± 25 to 222 ± 31 mg/dl in group A and from 277 ± 28 to 204 ±28 mg/dl in group B. Mean final dose of simvastatin was 34 and 31 mg/d respectively. This reduction was seen only in the LDL fraction of cholesterol: in group A from 209 ± 44 mg/dl to 140 ± 30 and in group B from 185 ± 21 to 104 ± 37 mg/dl. HDL cholesterol was unaffected by simvastatin treatment.

In summary, simvastatin effectively lowers total and LDL-cholesterol in patients with normal renal function and in patients with mild chronic renal failure.


Normal Renal Function Impaired Renal Function Total Cholesterol Level Familial Hypercholesterolemia Clofibric Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alberts AW, Chen J, Kuron G (1980) Mevinolin: a highly potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, and a cholesterol lowering agent. Proc Natl Acad Sci USA 77: 3957–3961.PubMedCrossRefGoogle Scholar
  2. 2.
    American Heart Association Steering Committee Medical and Community Program (1980) Risk factors and coronary disease. A statement for physicians. Circulation 62: 449.Google Scholar
  3. 3.
    Anderson P, Norbeck HE (1981) Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. Eur J Clin Pharmac 21: 209.CrossRefGoogle Scholar
  4. 4.
    Brown MS, Goldstein JL (1985) Arteriosklerose und Cholesterin: die Rolle der LDL Rezeptoren. Spektrum der Wissenschaft 1: 96–106.Google Scholar
  5. 5.
    Dawber TR (1980) The Framingham Study. The Epidemiology of Atherosclerotic Disease ( Harvard University Press: Cambridge).Google Scholar
  6. 6.
    Faed EM, McQueen EG (1979) Plasma half life of clofibric acid in renal failure. Br J Clin Pharmac 7: 407.Google Scholar
  7. 7.
    Helber A, Wambach G, Bottcher W, Weller P, Schmidt R (1980) Hypercholesterolaemia and hypertriglyceridaemia in patients with analgesic nephropathy. Nephron 26: 111–115.PubMedCrossRefGoogle Scholar
  8. 8.
    Helber A, Wambach G, Bottcher W, Finke K, Hahn R (1981) Erhöhtes kardiovaskulares Arterioskleroserisiko bei Analgetika-Nephropathie. Dtsch Med Wschr 106: 1369–1373.PubMedCrossRefGoogle Scholar
  9. 9.
    Lipid Research Clinic Program (1984) The Lipid Research Clinic Coronary Primary Prevention Trial Results. II. The Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Amer Med Ass 251: 365.CrossRefGoogle Scholar
  10. 10.
    Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P Hutunnen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart study. J Amer med Ass 260: 641.CrossRefGoogle Scholar
  11. 11.
    Steinberg D and the NIH Consensus Conference (1985) Lowering blood cholesterol to prevent heart disease. J Amer med Ass 253: 2080.CrossRefGoogle Scholar
  12. 12.
    Strategies for the prevention of coronary heart disease a policy statement of the European Atherosclerosis Society. Eur Heart J 8: 77–88 (1987).Google Scholar
  13. 13.
    Tyroler HA (1987) Lowering plasma cholesterol levels decrease risk of coronary heart disease: an overview of clinical trials. Hypercholesterolemia and atherosclerosis: pathogenesis and prevention. In: Steinberg D, Olefsky JM, eds. Contemporary Issues in Endocrinology and Metabolism. Vol 3 New York: Churchill Livingstone, 99–115.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • G. Wambach
  • R. Jacob
  • E. Danull
  • H. Eckardt

There are no affiliations available

Personalised recommendations